NDAORALTABLET
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
LOPRESSOR (metoprolol tartrate) by Rubicon Biotechnology is 12. First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPRESSOR (metoprolol tartrate) is a beta-1 selective adrenergic receptor blocking agent used to treat hypertension, angina, and heart failure. It works by slowing heart rate and decreasing cardiac output through preferential blockade of beta-1 receptors in the heart, with reduced effects on beta-2 receptors in bronchial and vascular tissue at therapeutic doses.
Launch
Early-stage launch with no linked job openings yet; team size and hiring will depend on market uptake and competitive positioning.
Mechanism of Action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.